Baird downgraded Oscar Health (OSCR) to Neutral from Outperform with a price target of $14, down from $28. The firm cites its caution on the healthcare exchange end market for the downgrade. Given Oscar’s recent pre-announced Q2 and 2025 outlook revision, Baird is increasingly cautious into 2026 and beyond. There is now significant complexity in projecting Oscar’s risk adjustment revenue, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OSCR:
- Oscar Health downgraded to Neutral from Outperform at Baird
- Moderately bullish activity in Oscar Health with shares up 1.8%
- Largest borrow rate increases among liquid names
- Oscar Health Faces Financial Instability Amid Pricing Challenges and Revised Earnings Expectations
- Oscar Health price target lowered to $11 from $17 at Barclays